Open access · US-GOV
via ClinicalTrials.gov Clinical trial
CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)
Authors not listed
US Department of Veterans Affairs · 2007
Abstract
The purpose of this study is to determine whether alpha-tocopherol, memantine (Namenda), or the combination will significantly delay clinical progression in mild to moderately demented patients with Alzheimer's disease compared to placebo.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Anonymous. (2007). CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD). <em>US Department of Veterans Affairs</em>. https://clinicaltrials.gov/study/NCT00235716
Vancouver
Anonymous. CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD). US Department of Veterans Affairs. 2007.
BibTeX
@misc{anon2007CSPARa,
title = {CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)},
author = {Anonymous},
journal = {US Department of Veterans Affairs},
year = {2007},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Florida Atlantic University 2007
Open access · US-GOV
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
NVP Healthcare 2026
Open access · US-GOV
36-week, Single-center, Randomized, Double-blind, Parallel-design, Placebo-controlled Trial to Determine the Safety and Efficacy of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Beijing Friendship Hospital 2015
Open access · US-GOV
Monetary Cost of Alzheimer's Disease in China: Study Protocol for a Cluster Randomized Observational Study
Biogen 2022
Open access · US-GOV
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease
Russell Swerdlow 2015
Open access · US-GOV
Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
AB Science 2026
Open access · US-GOV